A Phase 2a, Multi-Center, Randomized, Multiple-Dose Study to Evaluate the Safety, Tolerability and Efficacy of ACE-011 (hActRIIA-IgG1) in Patients With Osteolytic Lesions of Multiple Myeloma.
Phase of Trial: Phase II
Latest Information Update: 01 Jun 2014
At a glance
- Drugs Sotatercept (Primary) ; Melphalan; Prednisolone; Thalidomide
- Indications Cancer metastases; Multiple myeloma
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- Sponsors Celgene Corporation
- 07 Jun 2017 Biomarkers information updated
- 12 Mar 2010 Celgene Corporation added as trial sponsor as reported by ClinicalTrials.gov.
- 11 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History